This trial was only possible because of generous donations from supporters like you. Will you help fund the next breakthrough?
- Paypal accepted
- Mastercard accepted
- Visa accepted
- American Express accepted
We’re delighted about the results of the NLX-112 trial
Early results demonstrated that NLX-112 was safe, well tolerated and reduced symptoms of dyskinesia
Further analysis showed that participants had a significant reduction in movement symptoms, such as slowness, tremor and stiffness.
Encouragingly, these improvements were seen with relatively low doses of the drug. This suggests that higher doses and longer treatment could produce even better results.
This was a small scale trial so further studies are needed to prove the effectiveness of the drug. The next stage of the trial would likely look at the potential effectiveness in a larger group, over a longer time.
There'l be a third phase testing the drug on an even larger scale and if the next studies have positive results, NLX-112 could be available as a new treatment for Parkinson's by 2030.
Will you help back the next breakthrough? Fund more pioneering research like the NLX-112 trial by making a donation today.
The NLX-112 trial from the beginning
Look back on the aims of this trial from when the research started.